News Formal

AstraZeneca chief quits CSL board over $50 billion acquisition

  • 📰 smh
  • ⏱ Reading Time:
  • 18 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 11%
  • Publisher: 80%

Malaysia News News

Malaysia Malaysia Latest News,Malaysia Malaysia Headlines

AstraZeneca chief quits CSL board over $50 billion acquisition | MsEmmaK

AstraZeneca chief executive Pascal Soriot will leave CSL’s board just months after being appointed over fears of a potential future conflict of interest between the two biotechnology giants.

Based in Boston, Alexion develops treatments for rare diseases including in the blood and heart conditions, where CSL is a major player. Mr Soriot was not set to be directly involved in discussions about the AstraZeneca vaccine production and it was planned he would abstain from board issues where there was a potential conflict of interest.

We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 6. in MY
 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.

MsEmmaK I cant understand why no one is providing information on the CSL: manufacturing of AZ vaccine in Melbourne

MsEmmaK Are any Liberal involved in insider trading in this company ?

Malaysia Malaysia Latest News, Malaysia Malaysia Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

AstraZeneca chief quits CSL board over $50 billion acquisitionAstraZenaca’s Pascal Soriot will depart the CSL board next month to prevent potential conflicts of interest after his company bought a US immunology startup. Too late insider trading information already used
Source: theage - 🏆 8. / 77 Read more »